Quick Answer
Chemomab Therapeutics Ltd. reported Cash and Equivalents of $7.56 million for fiscal year 2025.
Chemomab Therapeutics Ltd. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $7.56M | +24.6% |
| 2024 | $6.07M | -34.7% |
| 2023 | $9.29M | -31.3% |
| 2022 | $13.52M | -11.0% |
| 2021 | $15.19M | +30.1% |
| 2020 | $11.67M | -33.6% |
| 2019 | $17.57M | +133.8% |
| 2018 | $7.52M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | $20.77M | +50.2% | +53.6% |
| December 31, 2022 | $13.52M | -11.0% | +25.9% |
| September 30, 2022 | $10.74M | -71.5% | +8.7% |
| June 30, 2022 | $9.88M | -78.2% | -28.5% |
| March 31, 2022 | $13.83M | -76.2% | -8.9% |
| December 31, 2021 | $15.19M | +30.1% | -59.8% |
| September 30, 2021 | $37.74M | +457.7% | -16.9% |
| June 30, 2021 | $45.40M | +414.5% | -22.0% |
- Chemomab Therapeutics Ltd. showed an increase of +24.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Chemomab Therapeutics Ltd.’s cash and equivalents has grown by 0.6% (from $7.52 million to $7.56 million).
- The most recent figure is from Chemomab Therapeutics Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: